Lantheus (LNTH) has agreed to be acquired and taken private by Curium in an up to $8 billion deal that will combine the strengths of the two radiopharmaceutical rivals.
Curium US will pay $102.50 per Lantheus share in cash at closing, plus up to $12 per share in future milestone-based payments through 2030, the companies said Monday.
The transaction value represents a 21% premium to Lantheus' closing price on May 21, the last trading day before media speculation began about a potential sale, the statement said.
The deal combines Curium's theranostics portfolio and global manufacturing platform with Lantheus' US radiodiagnostics business.
"Combining strategically with Curium brings together two pioneers with complementary strengths and a shared passion for nuclear medicine," Lantheus Chief Executive Mary Anne Heino said.
The deal, which requires Lantheus shareholders' consent and regulatory approvals, is projected to close in the first half of 2027. Upon closing, Lantheus will cease to be a publicly traded company.
"Lantheus' complementary business accelerates our strategy with a robust US commercial infrastructure, a complementary F18-isotope based prostate diagnostics franchise and marks our entry in the US market for diagnostic solutions targeting neurology and echocardiography," Curium CEO Renaud Dehareng said.
Curium is controlled by investment firm CapVest Partners. A recapitalization last year valued Curium Group at roughly $7 billion, the company said.
In May, Lantheus reported first-quarter adjusted earnings of $1.46 per share, compared with $1.53 a year earlier. Revenue rose 1.2% to $377.3 million.
Lantheus canceled its upcoming second-quarter earnings conference call and suspended its 2026 financial guidance due to the pending transaction. Shares of Lantheus were up 2.5% in Monday trade.
Wedbush Securities sees no antitrust overlap between Curium and the largely-domestic commercial footprint of Lantheus.
Price: $102.22, Change: $+2.58, Percent Change: +2.58%



